Biomarker für chronisch-entzündliche Erkrankungen

详细信息    查看全文

• 作者：Dr. D. Holzinger ; D. F?ll
• 关键词：Labordiagnostik ; Entzündung ; Krankheitsaktivit?t ; Juvenile idiopathische Arthritis ; Entzündliche Darmerkrankungen ; Laboratory diagnostics ; Inflammation ; Disease activity ; Juvenile idiopathic arthritis ; Inflammatory bowel diseases
• 刊名：Zeitschrift f篓鹿r Rheumatologie
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：74
• 期：10
• 页码：887-897
• 全文大小：738 KB
• 参考文献：1.Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428-35CrossRef PubMed
  2.Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191-197CrossRef PubMed
  3.Barton GM (2008) A calculated response: control of inflammation by the innate immune system. J Clin Invest 118:413-20PubMedCentral CrossRef PubMed
  4.Knowlton N, Jiang K, Frank MB et al (2009) The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 60:892-00PubMedCentral CrossRef PubMed
  5.Benito-Garcia E, Schur PH, Lahita R et al (2004) Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 51:1030-044CrossRef PubMed
  6.Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-54CrossRef PubMed
  7.Wacker C, Prkno A, Brunkhorst FM et al (2013) Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 13:426-35CrossRef PubMed
  8.Kay J, Morgacheva O, Messing SP et al (2014) Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 16:R40PubMedCentral CrossRef PubMed
  9.Kushner I, Samols D, Magrey M (2010) A unifying biologic explanation for ?high-sensitivity-C-reactive protein and ?low-grade-inflammation. Arthritis Care Res (Hoboken) 62:442-46CrossRef
  10.Gerss J, Roth J, Holzinger D et al (2012) Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 71:1991-997CrossRef PubMed
  11.Lachmann HJ, Goodman HJ, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361-371CrossRef PubMed
  12.Ravelli A, Varnier GC, Oliveira S et al (2011) Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 63:267-75CrossRef PubMed
  13.Flato B, Lien G, Smerdel A et al (2003) Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 30:386-93PubMed
  14.Habib HM, Mosaad YM, Youssef HM (2008) Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Invest 37:849-57CrossRef PubMed
  15.Keren DF (2002) Antinuclear antibody testing. Clin Lab Med 22:447-74CrossRef PubMed
  16.Sinico RA, Radice A (2014) Antineutrophil cytoplasmic antibodies (ANCA) testing: detection methods and clinical application. Clin Exp Rheumatol 32:S112–S117PubMed
  17.Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2:28-4CrossRef PubMed
  18.Kessel C, Holzinger D, Foell D (2013) Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol 147:229-41CrossRef PubMed
  19.Foell D, Wulffraat N, Wedderburn LR et al (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303:1266-273CrossRef PubMed
  20.Rothmund F, Gerss J, Ruperto N et al (2014) Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 66:949-55CrossRef
  21.De Jager W, Hoppenreijs EP, Wulffraat NM et al (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66:589-98CrossRef
  22.Prideaux L, De Cruz P, Ng SC et al (2012) Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 18:1340-355CrossRef PubMed
  23.Sellin JH, Shah RR (2012) The promise and pitfalls of serologic testing in inflammatory bowel disease. Gastroenterol Clin North Am 41:463-82CrossRef PubMed
  24.Dabritz J, Bonkowski E, Chalk C et al (2013) Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol 108:1901-910CrossRef PubMed
  25.Nylund CM, D’mello S, Kim MO et al (2011) Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease. J Pediatr Gastroenterol Nutr 52:542-48CrossRef PubMed
  26.Peterson CG, Sangfelt P, Wagner M et al (2007) Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scan J Clin Lab Invest 67:810-20CrossRef
  27.Lettesjo H, Hansson T, Pet
• 作者单位：Dr. D. Holzinger (1)
  D. F?ll (1)
  
  1. Klinik für P?diatrische Rheumatologie und Immunologie, Universit?tsklinikum Münster, Albert-Schweitzer-Campus?1, Geb?ude?W30, 48149, Münster, Deutschland
  
• 刊物主题：Internal Medicine; Rheumatology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1435-1250

文摘

Inflammatory disorders of childhood, such as juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) are a challenge for laboratory diagnostics. Firstly, the classical inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) often inadequately reflect disease activity but on the other hand there are few specific biomarkers that can be helpful in managing these diseases. Acute phase proteins reflect the systemic inflammatory response insufficiently as their increase is only the indirect result of local inflammatory processes. Modern inflammation diagnostics aim to reflect these local processes and to allow precise monitoring of disease activity. Experimental biomarkers, such as S100 proteins can detect subclinical inflammatory activity. In addition, established laboratory parameters exist for JIA [antinuclear antibodies (ANA), rheumatoid factor (RF), antibodies against cyclic citrullinated peptide (anti-CCP)] and for chronic IBD (fecal calprotectin) that are useful in the treatment of these diseases. Keywords Laboratory diagnostics Inflammation Disease activity Juvenile idiopathic arthritis Inflammatory bowel diseases